COFCO Biotechnology Future Growth
Future criteria checks 3/6
COFCO Biotechnology is forecast to grow earnings and revenue by 104.1% and 1.8% per annum respectively. EPS is expected to grow by 105.2% per annum. Return on equity is forecast to be 5.7% in 3 years.
Key information
104.1%
Earnings growth rate
105.2%
EPS growth rate
Chemicals earnings growth | 39.6% |
Revenue growth rate | 1.8% |
Future return on equity | 5.7% |
Analyst coverage | Low |
Last updated | 30 Apr 2024 |
Recent future growth updates
Recent updates
COFCO Biotechnology Co., Ltd. (SZSE:000930) Surges 39% Yet Its Low P/S Is No Reason For Excitement
Oct 14We Think COFCO Biotechnology (SZSE:000930) Has A Fair Chunk Of Debt
Sep 30COFCO Biotechnology Co., Ltd. (SZSE:000930) Looks Inexpensive But Perhaps Not Attractive Enough
Jul 17COFCO Biotechnology (SZSE:000930) Is Carrying A Fair Bit Of Debt
Jun 03Returns On Capital Signal Tricky Times Ahead For COFCO Biotechnology (SZSE:000930)
Apr 17COFCO Biotechnology Co., Ltd.'s (SZSE:000930) Price Is Right But Growth Is Lacking
Mar 07Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 21,543 | 705 | N/A | 1,454 | 1 |
12/31/2025 | 20,659 | 488 | N/A | 927 | 1 |
12/31/2024 | 20,404 | 81 | N/A | 291 | 1 |
9/30/2024 | 20,782 | -259 | 335 | 791 | N/A |
6/30/2024 | 20,980 | -205 | 1,564 | 2,054 | N/A |
3/31/2024 | 20,588 | -578 | 2,690 | 3,225 | N/A |
12/31/2023 | 20,379 | -602 | 1,323 | 1,958 | N/A |
9/30/2023 | 19,743 | -240 | -347 | 335 | N/A |
6/30/2023 | 18,619 | -63 | -1,016 | -391 | N/A |
3/31/2023 | 19,060 | 711 | -2,498 | -1,909 | N/A |
1/1/2023 | 19,918 | 1,059 | 143 | 708 | N/A |
9/30/2022 | 20,370 | 1,160 | 480 | 1,235 | N/A |
6/30/2022 | 22,142 | 1,215 | 1,840 | 2,712 | N/A |
3/31/2022 | 23,320 | 1,123 | 3,186 | 4,259 | N/A |
1/1/2022 | 23,560 | 1,130 | 3,732 | 4,842 | N/A |
9/30/2021 | 24,011 | 994 | 1,188 | 2,354 | N/A |
6/30/2021 | 22,630 | 928 | -1,665 | -555 | N/A |
3/31/2021 | 21,460 | 848 | -2,466 | -1,434 | N/A |
12/31/2020 | 19,909 | 593 | -3,898 | -2,911 | N/A |
9/30/2020 | 19,569 | 737 | -1,061 | -180 | N/A |
6/30/2020 | 19,883 | 772 | 930 | 1,843 | N/A |
3/31/2020 | 18,935 | 636 | 1,297 | 2,171 | N/A |
12/31/2019 | 19,472 | 593 | 2,749 | 3,650 | N/A |
9/30/2019 | 18,424 | 332 | 2,456 | 3,289 | N/A |
6/30/2019 | 17,720 | 304 | 13 | 865 | N/A |
3/31/2019 | 17,850 | 430 | -1,111 | -246 | N/A |
12/31/2018 | 17,704 | 483 | -1,792 | -923 | N/A |
9/30/2018 | 24,480 | 1,254 | -499 | 894 | N/A |
6/30/2018 | 21,848 | 1,070 | N/A | 1,483 | N/A |
3/31/2018 | 18,821 | 967 | N/A | 1,647 | N/A |
12/31/2017 | 15,892 | 929 | N/A | 2,017 | N/A |
9/30/2017 | 6,164 | 237 | N/A | 1,239 | N/A |
6/30/2017 | 5,898 | 339 | N/A | 1,022 | N/A |
3/31/2017 | 5,854 | 232 | N/A | 888 | N/A |
12/31/2016 | 5,603 | 127 | N/A | 785 | N/A |
9/30/2016 | 5,446 | -801 | N/A | 441 | N/A |
6/30/2016 | 5,593 | -1,083 | N/A | 533 | N/A |
3/31/2016 | 6,186 | -1,265 | N/A | 389 | N/A |
12/31/2015 | 6,457 | -1,418 | N/A | -114 | N/A |
9/30/2015 | 6,704 | -509 | N/A | -662 | N/A |
6/30/2015 | 7,155 | -312 | N/A | -554 | N/A |
3/31/2015 | 6,930 | -166 | N/A | -178 | N/A |
12/31/2014 | 7,153 | 35 | N/A | 207 | N/A |
9/30/2014 | 7,102 | 24 | N/A | 578 | N/A |
6/30/2014 | 7,074 | 32 | N/A | 781 | N/A |
3/31/2014 | 7,186 | 39 | N/A | 906 | N/A |
12/31/2013 | 7,340 | 51 | N/A | 738 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 000930 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.8%).
Earnings vs Market: 000930 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 000930 is expected to become profitable in the next 3 years.
Revenue vs Market: 000930's revenue (1.8% per year) is forecast to grow slower than the CN market (13.9% per year).
High Growth Revenue: 000930's revenue (1.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 000930's Return on Equity is forecast to be low in 3 years time (5.7%).